Pier Capital LLC Reduces Stock Position in Omnicell, Inc. $OMCL

Key Points

• Pier Capital LLC trimmed its stake in Omnicell by 34.6% in Q3, selling 61,211 shares and ending the period with 115,714 shares (about 0.26% ownership) worth roughly $3.52 million.
• Omnicell missed quarterly EPS ($0.40 vs. $0.47 expected) while revenue roughly matched forecasts; the company set Q1 2026 EPS guidance of $0.260–$0.360 and FY2026 guidance of $1.650–$1.850, and analysts' consensus is a "Moderate Buy" with an average target of $54.50.
• An insider sale saw EVP Corey J. Manley sell 6,106 shares at $49.90 (a 6.24% reduction in his position); company insiders now own about 2.52% of Omnicell.

Pier Capital LLC trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 34.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 115,714 shares of the company's stock after selling 61,211 shares during the period. Pier Capital LLC owned about 0.26% of Omnicell worth $3,523,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Omnicell in the 2nd quarter valued at approximately $26,000. First Horizon Corp acquired a new position in Omnicell during the third quarter worth $31,000. Farther Finance Advisors LLC boosted its position in Omnicell by 784.8% during the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company's stock worth $36,000 after purchasing an additional 1,036 shares in the last quarter. LSV Asset Management purchased a new stake in Omnicell during the third quarter worth $97,000. Finally, Tower Research Capital LLC TRC grew its holdings in Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock valued at $146,000 after purchasing an additional 3,932 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Performance

Omnicell stock opened at $35.10 on Friday. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 877.72, a PEG ratio of 1.34 and a beta of 0.79. The stock has a fifty day moving average of $43.98 and a two-hundred day moving average of $38.42. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million during the quarter, compared to analysts' expectations of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on OMCL. Wells Fargo & Company raised their price target on Omnicell from $43.00 to $52.00 and gave the company an "overweight" rating in a research report on Monday, January 5th. Bank of America upgraded shares of Omnicell from a "neutral" rating to a "buy" rating and set a $70.00 price objective on the stock in a research report on Wednesday, February 4th. Wall Street Zen cut shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. Zacks Research upgraded shares of Omnicell from a "strong sell" rating to a "hold" rating in a report on Tuesday. Finally, Piper Sandler restated an "overweight" rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $54.50.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the firm's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares of the company's stock, valued at $4,574,532.60. This trade represents a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.52% of the company's stock.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.